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Abstract 
Group IVA cytosolic phospholipase A2α (cPLA2α) plays a role in the microbicidal 
machinery of immune cells by translocating to phagosomes to initiate the production of 
antimicrobial eicosanoids. In the present work we have studied the involvement of the 
cationic cluster of cPLA2α (Lys488/Lys541/Lys543/Lys544) in the translocation of cPLA2α 
to the phagosomal cup in human macrophages responding to opsonized zymosan. 
Phagocytosis was accompanied by an increased mobilization of free arachidonic acid, 
which was almost completely abrogated by pyrrophenone. In transfected cells a 
catalytically active EGFP-cPLA2α translocated to the phagocytic cup, which was 
corroborated by frustrated phagocytosis experiments utilizing immunoglobulin G-coated 
plates. However, a cPLA2α mutant in the polybasic cluster Lys488/Lys541/Lys543/Lys544, 
that cannot bind the anionic phospholipid phosphatidylinositol 4, 5-bisphosphate (PIP2), 
did not translocate to the phagocytic cup. Moreover, an EYFP-cPLA2α and an ECFP-
pleckstrin homology (PH) domain of the PLCδ1 construct that specifically recognizes 
endogenous PIP2 in the cells, both localized at the same sites on the phagosome. High 
cellular expression of the PH domain inhibited EYFP-cPLA2α translocation. On the 
other hand, two other members of the phospholipase A2 superfamily of enzymes were 
studied as well, namely group V secreted phospholipase A2 and group VIA calcium-
independent phospholipase A2, but the results indicated that neither of these are 
involved in zymosan phagocytosis by human macrophages. Collectively, these data 
indicate that the polybasic cluster Lys488/Lys541/Lys543/Lys544 of cPLA2α regulates the 
subcellular localization of cPLA2α in intact immune cells under physiologically relevant 
conditions.  
 
 
 2
ABBREVIATIONS: AA, arachidonic acid; PLA2, phospholipase A2; cPLA2α, group 
IVA cytosolic phospholipase A2; iPLA2, calcium-independent phospholipase A2; sPLA2, 
secreted phospholipase A2; sPLA2-V, group V secreted phospholipase A2; BEL, 
bromoenol lactone; bis-BODIPY FL C11-PC, 1,2-bis-(4,4-difluoro-5,7-dimethyl-4-
bora-3a, 4a-diaza-sindecane-3-undecanoyl)-sn-glycero-3-phosphocholine; PLCδ-PH, 
pleckstrin homology domain of  PLCδ-PH; PIP2, phosphatidylinositol 4,5-bisphosphate. 
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Introduction 
Phospholipase A2 (PLA2) enzymes cleave membrane phospholipids at the sn-2 position 
of the glycerol backbone, releasing a free fatty acid and a lysophospholipid [1]. One of 
the better studied roles of PLA2 enzymes is their involvement in inflammatory 
processes, due to their ability to liberate free arachidonic acid (AA) from membrane 
phospholipids [2-5]. Free AA will in turn be oxygenated by specific enzymes to 
generate a wide variety of compounds with potent pro- and anti-inflammatory actions, 
collectively called the eicosanoids [6, 7]. Some of these compounds have also been 
described as important bactericidal agents [8].   
 Of the many existing PLA2 enzymes, only one, the group IVA PLA2 (also 
known as cytosolic phospholipase A2α, (cPLA2α) manifests specificity for AA-
containing phospholipids [9]. Today it is widely accepted that cPLA2α is the key 
enzyme in AA release leading to physiological and/or pathophysiological eicosanoid 
production [9-11]. Structurally, cPLA2α possesses a C2 domain containing the binding 
site for Ca2+ --and a binding site for ceramide-1 phosphate as well [12]--, and a catalytic 
domain, where the residues involved in enzymatic activity are located [9]. The catalytic 
domain also contains a cluster of cationic amino acids (Lys488, Lys541, Lys543, and 
Lys544) that may mediate enzyme binding to anionic phospholipids in membranes [13]. 
In fact, in vitro, anionic phospholipids such as PIP2, PI(3,4,5)P3 and PI(3,4)P2 strongly 
increase the cPLA2α specific activity when incorporated into the vesicle substrate [14, 
15]. Mutation of the aforementioned polybasic 4-Lys cluster eliminates the activating 
effect of PIP2 on cPLA2α activity [13]. Also, by plasmon resonance experiments it has 
been demonstrated that PIP2 activates cPLA2α by increasing the catalytic efficiency of 
the enzyme as a result of increasing membrane penetration [16]. In live cells, exogenous  
PIP2 and PI(3,4)P2 induce the translocation of cPLA2α to the intracellular membranes 
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[17]. More recently, it has been described that mutation of the Lys488, Lys543, and Lys544, 
decreases AA release in cells activated by serum, pointing to an important role for that 
cluster in cPLA2 activation under physiological stimulation [18].    
Phagocytosis is a specialized process of cells of the innate immune system to 
engulf invading microorganisms, foreign particles and apoptotic cells and debris. 
Phagocytosis is initiated at the site of particle attachment, producing a polarized region 
within the membrane that enlarges as a pseudopod to engulf the particle and drive it into 
the cytoplasm, where it will be degraded [19]. It has been previously shown that 
cPLA2α translocates to the phagosomal cup during the ingestion of particles, and such a 
translocation appears to be important for in situ eicosanoid generation and efficient 
elimination of microbes [20-23]. However, the mechanism regulating this translocation 
remains largely unknown. Utilizing human macrophages responding to opsonized 
zymosan, we demonstrate in this work that translocation of cPLA2α to the phagocytic 
cup depends on an intact cationic cluster Lys488/Lys541/Lys543/Lys544) in the catalytic 
domain of the enzyme. These results reveal a novel role for the cluster and provide new 
insights into the complex cellular regulation of the cPLA2α.  
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Materials and Methods 
Materials - [5,6,8,9,11,12,14,15-3H]AA 200 Ci/mmol was purchased from Amersham 
Ibérica (Madrid, Spain). Zymosan labeled with Alexa Fluor 594 and bis-BODIPY FL 
C11-PC were from Molecular Probes (Carlsbad, CA). Ficoll-PaqueTM Plus was from GE 
Healthcare (Uppsala, Sweden). Gentamicin was purchased from Biowhittaker 
(Walkersville, MD). Human macrophage Nucleofection solution was from Amaxa 
(Gaithersburg, MD). Macrophage serum free medium and RPMI 1640 were purchased 
from GIBCO (Carlsbad, CA). The pEGFP-PLCδ1-PH domain construct with the 
pleckstrin domain from the PLCδ1 was kindly provided by Dr. Tobias Meyer (Stanford 
University Medical Center, Stanford, CA) [24]. The EGFP-cPLA2α plasmid, the mutant 
for the PIP2 binding site EGFP-4KE/A-cPLA2α, the iPLA2-VIA-EYFP plasmid, and the 
sPLA2-V-EGFP plasmid have been described elsewhere [17, 25, 26]. pDsRed-
Monomer-C1 was obtained from Clontech (Mountain View, CA). All other reagents 
were from Sigma.  
 
Cells - Human macrophages were obtained from Buffy coats of healthy volunteer 
donors obtained from the Centro de Hemoterapia y Hemodonación de Castilla y León 
(Valladolid, Spain). Briefly, blood cells were diluted 1:1 with PBS, layered over a 
cushion of Ficoll-Paque and centrifuged at 750 x g during 30 min. The mononuclear 
cellular layer was then recovered and washed three times with PBS, resuspended in 
RPMI supplemented with 2 mM L-glutamine, 40 μg/ml of gentamicin and allowed to 
adhere to plastic in sterile dishes for 2 h. Non-adherent cells were then removed by 
extensively washing with PBS. Macrophage differentiation was achieved by incubating 
the adhered monocytes in RPMI supplemented with 2 mM L-glutamine, 40 μg/ml of 
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gentamicin and 5% human serum for two weeks, in the absence of exogenous cytokine 
mixtures. 
 
Plasmid transfection - Human macrophages were transfected by the Nucleofection 
technique (Amaxa), following the kit specifications for human macrophages. Briefly, 
cells were harvested by treatment with trypsin for 90 min and then by gentle scrapping. 
After washing, the cells were resuspended in 100 μl Human Macrophage Nucleofector 
solution plus 5 μg of plasmid. Nucleofection was carried out using the program Y-010, 
and the cells were resuspended in 400 μl of macrophage serum free medium (GIBCO) 
plus 5% heat inactivated human serum.  
 
Synchronized phagocytosis - These experiments were carried out as described elsewhere 
with minor modifications [27]. Macrophages were seeded over glass coverslips, allowed 
to adhere and then washed with RPMI supplemented with 40 μg/ml gentamicin. Cells 
were then kept at 4ºC for 5 min, and opsonized zymosan was then added. After 15 min 
incubation, coverslips were transferred to plates with RPMI at 37ºC, and the 
phagocytosis was allowed to proceed for different periods of time. Reactions were 
stopped by fixation with 3% paraformaldehyde and 3% sacarose for 15 min if they were 
to be analyzed by microscopy. After 3 washes with PBS, the coverslips were mounted in 
glass slides with antifade medium. Samples were than analyzed by epifluorescent or 
confocal microscopy. 
 
Confocal microscopy. Transfected cells were seeded in MatTek dishes and allowed to 
adhere for 24 h in RPMI supplemented with 2 mM L-glutamine, 40 μg/ml of gentamicin 
and 5% human serum. Medium was then changed by HBSS with 10 mM HEPES and 
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1.3 mM CaCl2 and fluorescence was monitored by confocal a Bio-Rad Radiance 2100 
laser-scanning system coupled to a Nikon TE-2000U with a thermostatized chamber 
(Warner Instruments). The objective was CFI Plan Apo 60X, 1.4 numerical aperture, oil 
immersion. The fluorescence of ECFP was monitored at 457 nm argon excitation using 
the combination of a long pass barrier filter HQ470LP and a short pass filter HQ520SP. 
The fluorescence of EGFP was monitored at 488 nm Argon excitation using the 
combination of a long pass filter HQ500LP and a short pass filter HQ560SP. The EYFP 
was monitored at 514 nm Argon excitation and the filters HQ520LP and HQ560 SP. 
The Alexa Fluor 594 fluorescence was monitored at 543 nm HeNe excitation using a 
long band pass filter HQ570LP. 
 
AA release. Cells were labeled with 0.5 μCi/ml of [3H]AA overnight. Afterward,  the 
cells were washed three times with PBS supplemented with 0.5 mg/ml fatty acid  free-
bovine serum albumin and incubated with RPMI supplemented with 0.5 mg/ml fatty 
acid-free bovine serum albumin and 1% ITS. Cells were then stimulated and 
supernatants were removed at different time periods. Cells monolayers were overlaid 
with ice-cold phosphate buffer containing 0.05% Triton X-100 and scraped. 
Radioactivity was quantified by liquid scintillation counting and AA release was 
referred to total radioactivity for each condition.  
Frustrated phagocytosis – This was carried out as described by Marshall et al. [28]. 
Briefly, human macrophages were dislodged from the culture plates by trypsin 
treatment, and were resuspended in RPMI containing 10 mM HEPES and 2 mM EDTA. 
Cells were gently stirred for 2-3 hours to allow for the re-expression of membrane 
receptors. Cells were then washed, resuspended in RPMI containing 10 mM HEPES and 
2 mM MgCl2, and plated over MatTek dishes treated or not with 10 mg/ml pure IgG. 
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After 30 min at 37°C, the cells were monitored by confocal microscopy. Some pictures 
were obtained in the XZ axis to have a better view of the cell membranes attached to the 
glass.  In some experiments, the cells were labeled with 5 μM bis-BODIPY FL C11-PC 
for 30 min, washed twice and processed for frustrated phagocytosis.  Fluorescence was 
monitored by confocal microscopy using 488 argon excitation and the combination of a 
HQ500 long band pass filter and HQ560 short band pass filter. 
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Results 
Translocation of cPLA2α to the phagosome in zymosan-stimulated human macrophages.  
Human macrophages are capable of recognizing yeast-derived zymosan particles and 
engulf them. By using transfected cells, we detected the translocation of a chimeric 
construct EGFP-cPLA2α from the cytosol to the phagocytic cups (Fig. 1). Translocation 
of the enzyme was particularly prominent in non-sealed phagocytic cups (Fig 1, 10-15 
min). Once the phagosome was sealed and internalized, the EGFP-cPLA2α separated 
from it (Fig. 1, 60 min). Experiments were performed next to rule out the possibility that 
the increased fluorescence arising from EGFP-cPLA2α in the forming phagosome was 
due to an increased volume of cytoplasm imaged in the plane. This was addressed by  
imaging in the same cell the construct EGFP-cPLA2α and a monomeric form of DsRed 
—to correct for local variations in cytoplasmic volume— . Fig. 2 shows a clear increase 
in EGFP-cPLA2α fluorescence in the phagosomes that does not correspond with an 
increase in cytoplasmic volume (ratio EGFP-cPLA2α /DsRed) at any time, thus 
indicating that enzyme translocation actually occurs. 
 
Phagocytosis of opsonized zymosan activates cPLA2α in human macrophages - 
Zymosan induced a significant release of AA (and metabolites) to the extracellular 
medium, suggesting the activation of a PLA2 (Fig. 3A). This PLA2 was identified as 
cPLA2α on the basis of complete inhibition of the response by a low concentration of 
pyrrophenone, a cPLA2α inhibitor [29] (Fig. 3B).  
 To confirm that the cPLA2α that translocates to the phagocytic cup is 
functionally active, an experiment of frustrated phagocytosis was performed, utilizing 
glass plates coated with IgG [28]. Macrophages exposed to IgG-coated glass surfaces 
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responded by translocating the EGFP-cPLA2α to the membranes more proximal to the 
glass surface, but not to other cellular membranes (Fig. 4A, B and E). In this 
experiment, the IgG-coated glass would represent the phagocytosable particle [28]. 
Next, we loaded the cells with the fluorogenic phospholipase substrate 1,2-bis-(4,4-
difluoro-5,7-dimethyl-4-bora-3a, 4a-diaza-sindecane-3-undecanoyl)-sn-glycero-3-
phosphocholine (bis-BODIPY FL C11-PC) [30], and subjected them to the frustrated 
phagocytosis assay. A dramatic increase in fluorescence was observed, especially in the 
proximity of the IgG-coated glass (Fig. 4C, D and F), indicating that an A-type 
phospholipase is acting at that place (where the “phagosome” is being initiated). To 
confirm that such a phospholipase is actually cPLA2α, we conducted experiments in the 
presence of pyrrophenone (Fig. 4D and F). As expected, pyrrophenone, at doses as low 
as 1 µM, strongly blocked the fluorescence increase in the cells exposed to IgG-coated 
glass, indicating that such a fluorescence increase is mainly due to cPLA2α activation. 
Mutation of a four-lysine cluster in cPLA2α that is involved in binding of anionic 
phospholipids suppresses EGFP-cPLA2α translocation to the phagocytic cup -  We 
have previously described that mutations on Lys488, Lys541, Lys543 and Lys544 of 
cPLA2α result in a defective translocation of cPLA2α to intracellular membranes in 
response to exogenous PIP2 [17]. Because it is well described that PIP2 increases in the 
phagosome [31], we studied next the behavior of the 4-Lys mutant (EGFP-4KE/A-
cPLA2α) in macrophages exposed to opsonized zymosan. The results, as shown in Fig. 
5A, clearly indicated that this mutant does not translocate to the phagocytic cup in 
activated cells at any time tested, suggesting that a functional binding site in cPLA2α for 
anionic phospholipids is necessary for such a translocation to be observed. To further 
substantiate this observation, we performed experiments of frustrated phagocytosis, 
similar to those shown in Fig. 4, utilizing cells transfected with the EGFP-4KE/A-
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cPLA2α mutant. Fig. 5B shows that, unlike the wild type enzyme, the mutant did not 
translocate to the membranes that are closer to the IgG-coated plate. These data 
highlight the importance of the 4-Lys cluster for proper binding of cPLA2α to the 
phagosomal membranes. 
Experiments were conducted next to study a possible role for anionic 
phospholipids in cPLA2α translocation to the phagocytic cup. To this end, we took 
advantage of the PIP2-binding properties of a fluorescent chimeric protein of EGFP with 
the pleckstrin homology domain of the PLCδ1 (EGF-PLCδ1-PH) [28]. Figure 6A shows 
that, when transfected into human macrophages, the chimera labels the main cellular 
reservoir of PIP2, i.e. the plasma membrane [24]. Immediately after promoting PIP2 
hydrolysis by activating the cells with a calcium ionophore, the fluorescence disappears 
from the plasma membrane, and accumulates in the cytoplasm, as would be expected 
from a functional PH domain (Fig. 6A). By using this chimera, we confirmed in human 
macrophages previous observations by Botelho et al. [31], indicating that PIP2 levels 
increase at the phagocytic cup while the phagosome is being formed, and decrease when 
it seals (Fig. 6B).  
Subsequently, the cells were co-transfected with both constructs, namely ECFP-
PLCδ1-PH and EYFP-cPLA2α. In resting cells, ECFP-PLCδ1-PH was present only in 
the plasma membrane, whereas EYFP-cPLA2α was found primarily in the cytoplasm 
(Fig. 7). However, after exposure of the cells to opsonized zymosan both chimeric 
proteins localized at the forming phagocytic cups (Fig. 7B). There was no co-
localization in the cytoplasm of resting or stimulated cells. We noticed also that in those 
cells where ECFP-PLCδ1-PH construct was expressed at higher levels the translocation 
of the cPLA2α to the phagosomes was inhibited (Fig. 7 C).  
The behavior of EGFP-PLCδ1-PH and EGFP-cPLA2α were analyzed in more 
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detail by confocal analysis of z-stack series from cells that were engulfing particles at 
similar stages of phagocytosis (Figs. 8 and 9).  We observed that both constructs were 
enriched in the same sites of the phagosomes, especially along the particles and in the 
base. It is worth noting that translocation of the EGFP-cPLA2α to the base of some of 
the phagosome was more prominent than that of EGFP-PLCδ1-PH. It is possible that in  
the base of the phagosome other factors, in addition to or independently of PIP2, 
contribute to the translocation of cPLA2α.   
 
Secreted group V and cytosolic calcium-independent group VIA PLA2s do not 
translocate to the phagocytic cup - To address whether other PLA2s in addition to 
cPLA2α could also translocate to the phagocytic cup during phagocytosis of opsonized 
zymosan, we utilized human macrophages transfected with either sPLA2-V-EGFP or 
iPLA2-VIA-EYFP. In agreement with our previous studies in murine macrophages [25, 
32], sPLA2-V-EGFP was found in resting cells associated with secretory granules and 
Golgi-like structures (Fig 10A). iPLA2-VIA-EYFP had a mitochondrial localization in 
unstimulated cells (Fig. 10B), which is in accordance with previous estimates [33]. After 
the cells where challenged with opsonized zymosan, localization was studied between 
the chimeric proteins and the fluorescent particles. We failed to detect association of the 
fluorescence arising from either sPLA2-V-EGFP or iPLA2-VIA-EYFP to the phagocytic 
cups under any condition (Fig. 10). Thus, of the three major PLA2 classes potentially 
capable of generating lipid mediators during inflammation [2-5, 34], only the cPLA2α 
translocates to the phagocytic cup in human macrophages. 
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Discussion 
A major regulatory mechanism of cPLA2α activity in cells is the Ca2+-dependent control 
of the physical state of the enzyme. In resting cells, the enzyme resides in the cytosol 
and hence, having no access to its substrate in the membrane, has no activity. In 
stimulated cells cPLA2α translocates to the membrane in a Ca2+-dependent process, this 
resulting in phospholipid hydrolysis and free AA release [9]. Most of the research 
carried out to date has thoroughly documented the translocation of cPLA2α to 
intracellular membranes such as those of the nuclear envelope, Golgi complex or 
endoplasmic reticulum [9]. A few instances have been reported of translocation of 
cPLA2α to cellular membranes different to those indicated above [20, 35, 36].  This 
study adds to these studies by showing that the phagosomal membrane of human 
macrophages is also a site for cPLA2α translocation during activation conditions. 
Particularly relevant to our report is the work by Girotti et. al. showing translocation of 
cPLA2α to forming phagosomes in murine macrophages [20]. Although the molecular 
mechanism was not investigated, the authors noted that chelation of extracellular 
calcium decreased the total number of phagocytic events, but cPLA2α still remained 
associated to the lasting phagosomes at intracellular calcium levels equaling those of 
resting cells [20]. In previous work from our laboratory, we showed that introducing 
exogenous short-chain PIP2 into cells promotes the translocation of cPLA2α from 
cytosol to perinuclear membranes at basal levels of intracellular Ca2+ [17]. Moreover, 
other studies have demonstrated that PIP2 transiently increases in the forming 
phagosome and disappears after phagosome sealing, being undetectable in the sealed 
phagosome [31]. Intrigued by these observations, we speculated that translocation of 
cPLA2α to the forming phagosome could require  the cationic cluster of four Lys 
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(Lys488/Lys541/Lys543/Lys544) that is present in cPLA2α and has been shown to bind 
anionic phospholipids such as PIP2 [13]. Using confocal microscopy techniques, we 
document the localization of cPLA2α and a PIP2-binding construct, ECFP-PLCδ1-PH, in 
forming phagosomes. Also, high level expression of the ECFP-PLCδ1-PH inhibits the 
translocation of the cPLA2α to phagosomes. Moreover, mutation of the cationic cluster 
of Lys488, Lys541, Lys543 and Lys544 that serves as a PIP2-binding site, eliminates the 
ability of the enzyme to translocate to the phagosomal membrane. Collectively, these 
results provide the first example of a physiologically-relevant condition where the 
cationic cluster of cPLA2α participates in regulating enzyme association to membranes 
and hence,  its activity in intact cells.  
 The presence of cPLA2α at the membrane of the nascent phagosome may serve 
important pathophysiological roles, since during phagocytosis large quantities of 
eicosanoids are produced which could be involved in the killing of the ingested 
microorganism at the phagosome [8, 21-23]. In the mouse model, other PLA2s in 
addition of cPLA2α have been suggested to be related to phagocytic events. Particularly 
relevant to this work, it has been shown that group V secreted PLA2 also translocates to 
the phagosome in zymosan-stimulated murine peritoneal macrophages [23]. Intrigued 
by this report, we also studied the possible movement of sPLA2-V to phagosomes in our 
human macrophage cell system. We failed to detect translocation of a chimeric sPLA2-
V-EGFP protein to phagosomes in our systems. We had previously demonstrated that 
this chimeric sPLA2-V behaves the same as the native sPLA2-V protein in terms of 
biochemical properties, enzymatic activity and subcellular localization [25, 32]. There 
are many differences between the murine and human macrophage models of zymosan 
phagocytosis that may explain these different results. For instance, in murine 
macrophages, zymosan induces abundant AA release [37-43] and may be internalized 
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primarily via dectin-1 receptors [44]. However, human macrophages do not respond 
readily to zymosan by releasing AA, and opsonization of the particle appears to be 
required for full responses, which may occur primarily via Fc receptors. Thus, it appears 
likely that the different mechanisms of internalization of phagocytosable particles in 
mouse versus human may account, at least in part, for the remarkable differences in the 
translocation ability of sPLA2–V to the phagosomes.  
 The one other PLA2 that we investigated is iPLA2-VIA, a calcium-independent 
enzyme. Unlike cPLA2α and sPLA2 enzymes, the involvement of iPLA2-VIA in 
receptor-mediated AA mobilization appears not to be a general one, but to depend on 
cell type and stimulation conditions [2, 45-48]. Using a chimeric construct, iPLA2-VIA-
EYFP, we have detected no appreciable change in the subcellular localization of this 
enzyme during opsonized zymosan challenge; the enzyme always remained associated 
to mitochondria, which is consistent with previous data [33]. Thus, from the three major 
PLA2 families potentially capable of effecting AA release for eicosanoid production, 
only one, cPLA2α,  translocates to the phagosome in human cells.  
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Figure Legends 
 
Figure 1. Translocation of cPLA2α to the phagosome in zymosan-treated human 
macrophages. Human macrophages were transfected with the construct EGFP-cPLA2α, 
treated with 1 mg/ml opsonized-zymosan for the indicated times, fixed and analyzed by 
confocal microscopy. In panels A and E Alexa Fluor 594-labeled zymosan was used to 
better visualize the particles. Fluorescence arising from the EGFP-cPLA2α (green) or 
zymosan (red) is shown on the left column. Middle-column panels show a 
pseudocolored fluorescence intensity from the EGFP-cPLA2α. Panels on the right 
column show a detailed amplification of the phagosomes framed in the middle panels. 
Scale bar = 10 μM. 
 
Figure 2. Analysis of the translocation of cPLA2α and the monomeric DsRed to 
phagosomal membranes. Human macrophages were co-transfected with the construct 
EGFP-cPLA2α or the soluble  fluorescent protein DsRed (monomeric form). Cells were 
stimulated with opsonized zymosan, fixed, and fluorescence was analyzed by confocal 
microscopy at different times. A) The figure represents the fluorescence ratio EGFP-
cPLA2α / DsRed in phagosomes versus cytosol at each time point. At least 4 
phagosomes per cell were analyzed from many cells. B) Pictures of the cellular 
fluorescence of the EGFP-cPLA2α and the DsRed at different times of phagocytosis are 
shown. 
 
Figure 3. AA release in human macrophages challenged with opsonized zymosan. (A) 
Human macrophages labeled with [3H]AA were treated with 1 mg/ml opsonized 
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zymosan (black triangles) or vehicle (black squares). AA release was assessed at 
different times as described under Materials and Methods. (B) Cells labeled with 
[3H]AA were pretreated with 1 μM pyrrophenone (pyrr) or vehicle (control) for 30 min 
and then treated with 1 mg/ml opsonized zymosan (black bars) or vehicle (grey bars) for 
1 h.  
 
Figure 4. cPLA2α is functionally active in the phagosomal cup in human macrophages. 
(A) Cells transfected with EGFP-cPLA2 were subjected to a frustrated phagocytosis 
assay on non-coated glass (Ctrl) or IgG-coated glass (IgG), as indicated, and analyzed 
by confocal microscopy. Pictures of the XZ axis of the cells were taken. (B) The 
intensity of the fluorescence obtained in A was analyzed in pseudocolor. (C) Cells, 
labeled with bis-BODIPY FL C11-PC, were plated on non-coated glass (Ctrl) or on IgG-
coated glass (IgG) for 30 min, and fluorescence was analyzed by confocal microscopy. 
The mean of fluorescence intensity in Ctrl was 66 and in IgG was 128. (D) The cells 
were labeled with bis-BODIPY FL C11-PC and subjected to a frustrated phagocytosis 
assay. Pictures of the XZ axis of the cells were taken, and the intensity of the 
fluorescence was analyzed in pseudocolor. In the picture on the bottom, the cells were 
treated with 1 μM pyrrophenone (Pyrr). White bar = 10 μm. E) Statistical analysis of the 
fluorescence intensity in cells assayed for frustrated phagocytosis as in D. Data are 
represented as relative fluorescence intensities (mean fluorescence intensity in 
membranes closer to the glass/mean fluorescence intensity in the cytosol). At least 15 
different cells were analyzed.  
 
Figure 5. The mutant EGFP-4KE/A-cPLA2α does not translocate to the phagosome in 
human macrophages. A) Human macrophages transfected with the mutant EGFP-
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4KE/A-cPLA2α were subjected to synchronized phagocytosis with Alexa Fluor 594-
labeled opsonized zymosan for the indicted times, fixed and analyzed by confocal 
microscopy. Framed phagosomes have been enlarged and the intensity of the 
fluorescence analyzed by pseudocolor (left upper inserts at 15 and 30 min). B) Cells 
transfected with the construct EGFP-cPLA2α or EGFP-4KE/A-cPLA2α were subjected 
to a frustrated phagocytosis assay, and plated over non-coated glasses (Ctrl) or IgG- 
coated glasses (IgG) as indicated, and analyzed by confocal microscopy. Pictures of the 
XZ axis of the cells were taken and the intensity of the fluorescence obtained was 
analyzed in pseudocolor.  The figure is representative of more than 40 cells that were 
analyzed per experiment, and the experiment was repeated four times. White bar = 10 
μm. 
 
Figure 6. PIP2 accumulation in the forming phagosomes during zymosan phagocytosis 
in human macrophages. (A) Cells were transfected with the construct EGFP-PLCδ-PH  
and analyzed in vivo by confocal microscopy. Pictures were taken before (control) and 
after 5 min of treatment with 5 μM ionomycin (Iono 5 μM). (B) Cells were transfected 
with the construct EGFP-PLCδ-PH, treated with opsonized zymosan, an analyzed in 
vivo by confocal microscopy. Pictures were taken at different time points after exposure 
to zymosan, as indicated. The pictures on the bottom right correspond to the 
phagosomes selected with a dotted white box at each time point, and the fluorescence 
intensity has been analyzed in pseudocolor. 
 
Figure 7. Localization of ECFP-PLCδ1-PH and EYFP-cPLA2α during phagocytosis in 
human macrophages. Human macrophages, co-transfected with the ECFP-PLCδ1-PH 
and the EYFP-cPLA2α constructs, were subjected to synchronized phagocytosis using 
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Alexa Fluor 594-labeled opsonized zymosan, fixed at 0 (Control) and 15 min and 
analyzed by confocal microscopy (A). B) A cell with high expression of the construct 
ECFP-PLCδ1-PH is shown. In A and B, middle panels, fluorescence intensities are 
shown in pseudocolor, and detailed fluorescence in forming phagosomes is shown in 
panels to the right. 
 
Figure 8. Analysis of human macrophages transfected with EGFP-cPLA2α during 
phagocytosis of zymosan. Human macrophages transfected with the construction EGFP-
cPLA2α were treated with opsonized zymosan for 20 min, fixed, and fluorescence 
analyzed by confocal microscopy. A) Ten different z-stacks of the same cell are shown 
(from top to bottom). B) Pseudocolor analysis of the intensity of fluorescence of the cell 
in A is shown. C and D) Detailed phagosomes from B.  
 
Figure 9. Analysis of a human macrophage transfected with EGFP-PLCδ1-PH  during 
phagocytosis of zymosan. Human macrophages transfected with the construction EGFP- 
PLCδ1-PH were treated with zymosan for 20 min, fixed, and fluorescence analyzed by 
confocal microscopy. A) Ten different z-stacks of the same cell are shown (from top to 
bottom). B) Pseudocolor analysis of the intensity of fluorescence from some 
phagosomes is shown (white square in A).  
 
Figure 10. sPLA2-V and iPLA2-VIA do not translocate to the phagocytic cup in human 
macrophages. Cells transfected with the fluorescent constructs sPLA2-V-EGFP (A) or 
iPLA2-VIA-EYFP (B) were subjected to synchronized phagocytosis using Alexa Fluor 
594-labeled opsonized zymosan (op-zym) or vehicle (control) for 15 min, fixed and 
analyzed by confocal microscopy. Images are the projection to the Z axis of more than 
 29
13 stacks (0.25 μm each). Transmission images are shown in the right panel. White bar 
= 10 μm. 
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